Test Price
2,800 AEDโ Home Collection Available
ANOS1 Gene Kallmann Syndrome Type 1 Genetic Test | 2800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing with full gene coverage across all 14 exons.
- Premium Logistics: VIP Mobile Phlebotomy and Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across Dubai, Sharjah, and Abu Dhabi.
- Clinical Guidance: Mandatory pre-test genetic counseling session with pedigree documentation and telephonic post-test result interpretation by a board-certified genetic counselor.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731 prior to sample collection.
Molecular genetic test for definitive diagnosis of congenital hypogonadotropic hypogonadism with anosmia, enabling personalized endocrine and fertility management.
Test Overview & Methodology
The ANOS1 Gene Kallmann Syndrome Type 1 NGS Test sequences the entire ANOS1 gene using next-generation sequencing to identify pathogenic variants responsible for congenital hypogonadotropic hypogonadism with anosmia. This UAE-based molecular diagnostic provides a definitive genetic confirmation, enabling endocrinologists and geneticists to tailor puberty induction and fertility preservation strategies. The assay achieves greater than 98 percent variant detection sensitivity, including deep intronic and splice-site variants that Sanger-based methods routinely miss.
| Feature | Our Test (Precision / Method / Speed) | Closest Alternative (Sanger Single-Exon) |
|---|---|---|
| Technology | NGS full gene sequencing (all 14 exons plus flanking regions) | Sanger sequencing of selected exons only |
| Diagnostic Yield | Greater than 98 percent variant detection including deep intronic and regulatory variants | Approximately 70 to 80 percent, misses rare pathogenic variants and splice-site alterations |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
| Sample Requirement | Peripheral whole blood, extracted DNA, or buccal swab | Peripheral whole blood only |
| Genetic Counseling | Mandatory pre-test session with pedigree drawing and post-test disclosure | Not routinely offered |
Physician Insight & Safety Protocols
โGenetic confirmation of an ANOS1 variant provides families with a clear molecular diagnosis, but clinical management must integrate hormone profiling, MRI imaging, and longitudinal endocrine follow-up. This test offers diagnostic clarityโit does not replace specialist-led treatment decisions. Patients and caregivers should continue all prescribed therapies, including hormone replacement or growth hormone, until explicitly advised otherwise by their managing specialist.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Pre-Test Preparation and Medication Safety
Important Clinical Guidance Before Sample Collection
- Maintain all current medications including hormone therapies, growth hormone, and gonadotropins unless your endocrinologist advises a temporary hold.
- Pre-test genetic counseling is mandatory and must be completed at least 48 hours prior to blood draw to allow informed consent and pedigree documentation.
- No fasting or dietary restrictions are required; the test can be performed at any time of day.
Exclusion Criteria and Emergency Red Flags
Situations Requiring Immediate Medical Attention
- This test is not for acute medical emergencies; do not delay care if experiencing severe headache, sudden vision loss, acute hearing changes, or signs of adrenal crisis such as vomiting, severe dehydration, or hypotension.
- Not a standalone fertility assessment; must be interpreted alongside hormonal evaluation including LH, FSH, testosterone, and inhibin B levels.
- Patients with active bleeding disorders, severe anemia, or those on anticoagulant therapy should consult their physician before venipuncture.
Patient FAQ & Clinical Guidance
1. What is the ANOS1 gene and why is this test ordered?
The ANOS1 gene provides instructions for producing anosmin-1, a protein essential for the normal migration of gonadotropin-releasing hormone neurons and olfactory nerve fibers. Pathogenic variants in ANOS1 cause Kallmann syndrome type 1, characterized by congenital hypogonadotropic hypogonadism and anosmia. This test is ordered when a patient presents with delayed or absent puberty, infertility, and an inability to smell, providing a definitive molecular diagnosis that guides hormone replacement therapy, fertility treatment, and family screening.
2. How is the sample collected and are there special preparations?
A simple peripheral blood draw or buccal swab is all that is required; no fasting, dietary changes, or medication adjustments are needed. Our DHA-licensed phlebotomist will visit your home or designated location anywhere in Dubai, Sharjah, or Abu Dhabi between 8 AM and 11 PM. A mandatory pre-test genetic counseling session must be completed prior to collection to document family history through a pedigree chart and obtain informed consent. Patients on anticoagulant therapy should confirm with their physician before venipuncture.
3. What is the turnaround time and how will I receive results?
Results are ready within 3 to 4 weeks from sample receipt at our laboratory. They are delivered securely via our encrypted patient portal accompanied by a telephonic result disclosure session with a genetic counselor. The comprehensive clinical report includes the variant description, pathogenicity classification according to ACMG/AMP guidelines, and management recommendations. Written copies are also transmitted through your preferred secure channel, and a follow-up consultation with the referring physician is encouraged for treatment planning.
UAE Regulatory & Data Privacy Adherence
All genetic data processing, storage, and transmission for the ANOS1 Gene Kallmann Syndrome Type 1 Genetic Test is conducted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory holds ISO 9001:2015 certification (Certificate No. INT/EGQ/2509DA/3139) and operates under the regulatory oversight of the Dubai Health Authority. Genetic counseling and informed consent processes meet all mandatory DHA standards for predictive genetic testing.
Clinical & Logistical Metadata
| Test Name | ANOS1 Gene Kallmann Syndrome Type 1 Genetic Test (NGS Full Gene Sequencing) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood, Extracted DNA, or Buccal Swab |
| Methodology Used | Next-Generation Sequencing (NGS) โ Full Gene Sequencing, all 14 exons plus flanking intronic regions |
| ICD-10-CM Code | E23.0 (Hypogonadotropic hypogonadism with anosmia) |
| LOINC Code | 81321-3 (ANOS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians